The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
Genmab A/S has announced that the FDA has approved the use of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone,...
The FDA has added more data to the indication of Kyprolis with dexamethasone �specifically, data that showed Kyprolis from Amgen,,...
The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of ...
The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/ Dexamethasone will prolong the time...
Genmab A/S announced that the Phase III POLLUX study (MMY3003) of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone versus...
Amgen announced positive results from a planned overall survival (OS) interim analysis of the Phase III head-to-head ENDEAVOR trial. The...
Ocular Therapeutix has submitted a New Drug Application (NDA) to the FDA for Dextenza (sustained release dexamethasone) 0.4mg Intracanalicular Depot,...